FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. today announced the appointment of Mara G. Aspinall to its Board of Directors, and the addition of James L. Dunn, Jr. to its senior leadership team.
Mara Aspinall most recently served as President and Chief Executive Officer of the Roche Group’s Ventana Medical Systems, a global leader in tissue-based cancer diagnostics. She previously spent 12 years with Genzyme Corporation as President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was also the Founder, CEO and Director of cancer diagnostics company On-Q-ity, and has spearheaded many initiatives to educate policymakers about diagnostics and personalized medicine. Ms. Aspinall served for 15 years on the Board of the Dana Farber Cancer Institute, currently chairs the Arizona Biosciences Board, and holds an M.B.A. from Harvard Business School and a B.A. from Tufts University.
“We are excited and fortunate to have a leader of Mara’s caliber and track record join our Board,” said Dan Bradbury, Chairman of the Board of Directors of Castle Biosciences. “Her deep expertise in the diagnostics field will be invaluable to the company as we continue to advance the clinical adoption and commercialization of our growing lineup of practice-changing tests.”
The Company also welcomed James L. Dunn, Jr. as its Chief Financial Officer. With over 20 years of public company experience, Mr. Dunn has served in both CFO and General Counsel roles across various industries. He most recently served as CFO of Applied Optoelectronics, Inc., and successfully managed its IPO. He began his career as a Co-Founder and CFO of Pentegra Dental Group (now iLinc) from its IPO in 1998 to its successful sale in 2008. He is a certified public accountant and attorney, holding a B.B.A. in Accounting from Texas A&M University, and a J.D. from Southern Methodist University.
“We continue to broaden our senior management ranks as we bring Jim Dunn on board as CFO,” said Derek Maetzold, President and Chief Executive Officer. “I look forward to Jim’s contributions as our team continues to execute on the Company’s strategic and financial objectives.”
About Castle Biosciences
Castle Biosciences is a molecular diagnostics and prognostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company offers tests providing actionable information that improve patient care through advances in cancer staging accuracy and treatment precision in uveal and cutaneous melanoma, esophageal and brain cancers. More information can be found at www.castlebiosciences.com.